Reducing Innate Inflammation in New Onset Type 1 Diabetes

Reducing Innate Inflammation in New Onset Type 1 Diabetes With Lactiplantibacillus Plantarum

This study aims to determine whether Lactiplantibacillus plantarum 299v (Lp299v) supplementation will reduce systemic inflammation and prolong residual beta cell function in individuals newly diagnosed with Type 1 diabetes. The investigators hypothesize that probiotic-induced alterations in the intestinal microbiota may favorably alter the post-onset disease state.

Study Overview

• Status: Active, not recruiting
• Conditions: Type 1 Diabetes; Type 1 Diabetes Mellitus; type1diabetes
• Intervention / Treatment: Dietary supplement: Lactiplantibacillus plantarum; Other: Placebo

Detailed Description

For individuals newly diagnosed with Type 1 diabetes, this clinical trial will assess whether probiotic supplementation has efficacy in reducing the endogenous systemic innate inflammatory state known to exist in newly diagnosed Type 1 diabetes and whether this reduction correlates with preservation of endogenous insulin production as measured by stimulated C-peptide during mixed meal tolerance testing (MMTT). The innate inflammatory state will be measured by plasma-induced transcriptional assay and quantified as a composite inflammatory index. Mixed meal tolerance testing is the gold standard measure of endogenous insulin production. During this test, serial blood c-peptide levels are collected over 2 hours in response to challenge with a nutritional drink containing a mix of protein, fat, and carbohydrate and the C-peptide area under the curve is calculated.

Using a randomized, placebo-controlled design, the investigators will measure changes in systemic inflammation (primary outcome) and beta cell function (secondary outcome) after six months of daily treatment with either Lp299v supplementation or placebo. These measures of plasma-induced transcriptional assay and MMTT will be related to markers of beta cell stress, the composition of the gut microbiota, analysis of the plasma metabolome, and levels of microbial antigen exposure.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Medical College of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 45 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. ≤ 100 days from T1D diagnosis based on ADA criteria
2. > 21 days from T1D diagnosis or metabolically stable per study physician assessment
3. Males and females 3-45 years of age, inclusive, at time of screening visit
4. Peak MMTT stimulated C-peptide ≥ 0.2 nmol/L
5. Positive for at least 1 diabetes autoantibody (excluding mIAA in those who have received ≥ 2 weeks of exogenous insulin therapy) either through clinically obtained labs at time of diagnosis or as obtained at the screening visit
6. Females of child-bearing potential (defined as any female who has reached menarche (first menses), excluding those who have had a hysterectomy or are post-menopausal and must be willing to use effective birth control (which may include abstinence)) from screening visit until final study visit
7. Willing and able to give informed consent or have parent or legal guardian provide informed consent if the subject is < 18 years of age

Exclusion Criteria:

1. Probiotic supplement use within the past month
2. Antibiotic use within the past month
3. Concurrent or recent (within the past 30 days of screening) use of non-insulin therapies aimed to control hyperglycemia
4. Females who are pregnant or lactating
5. Chronic inflammatory or autoimmune disease with exception of stable thyroid disease
6. Uncontrolled celiac disease (i.e., consuming gluten) or actively being evaluated for possible celiac disease (i.e., clinically obtained tissue transglutaminase IgA titers above reference range, being referred to gastroenterology for possible endoscopy, etc.)
7. Use of glucocorticoids or other immunosuppressive agents within 30 days of screening MMTT
8. Use of medications known to influence glucose tolerance
9. Dairy allergy
10. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Group; Subjects will be randomized to the treatment or placebo group. The treatment is a capsule taken by mouth once a day for 6 months.	Dietary supplement: Lactiplantibacillus plantarum; Probiotic capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages; Other Names: Lp299v
Placebo Comparator: Placebo Group; Subjects will be randomized to the treatment or placebo group. The placebo is a capsule taken by mouth once a day for 6 months.	Other: Placebo; Placebo capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in composite inflammatory index after probiotic supplementation	Investigators will examine the effect of probiotic supplementation on the endogenous innate inflammatory state in youth newly diagnosed with T1D, as measured by plasma-induced transcription and analyzed using a composite inflammatory index score. The investigators hypothesize that the subjects receiving the probiotic will have less inflammation (as measured by transcriptional analysis) than the participants in the placebo group.	5 years (duration of study)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of stimulated C-peptide Area Under the Curve (AUC) decline after probiotic supplementation	Investigators will examine the rate of C-peptide decline, as measured by C-peptide AUC in youth newly diagnosed with T1D. The investigators hypothesize that the subjects receiving the probiotic for 6 months will have a slower rate of decline than the subjects in the placebo group.	5 years (duration of study)
Markers of beta cell function	Investigators will examine the effect of probiotic supplementation on beta cell function by measuring proinsulin levels, ratio of proinsulin to C-peptide and islet amyloid polypeptide to pro-islet amyloid polypeptide ratio.	5 years (duration of study)
Microbial composition as measured by 16s rRNA sequencing	Investigators will examine the effect of probiotic supplementation using 16s rRNA sequencing to determine the composition of the intestinal microbiota. Investigators hypothesize the composition of the intestinal microbiota will differ before and after treatment with probiotic supplementation.	5 years (duration of study)
Markers of systemic microbial antigen exposure	Gut leakiness will be measured by examining the levels of microbial antigens in the plasma before and after treatment and correlating these antigen levels with the changes in the composition of the gut bacteria. It is hypothesized that changes in antigen levels and gut bacteria will only be seen in the participants receiving the probiotic. It is further hypothesized that those with the greatest reduction in antigens will have the most significant changes in gut bacteria composition.	5 years (duration of study)
Regulatory T cell abundance and activity by flow cytometry	Investigators will examine the effect of probiotic supplementation on regulatory T cell abundance and activity.	5 years (duration of study)
Monocyte abundance and activity by flow cytometry	Investigators will examine the effect of probiotic supplementation on monocyte abundance and activity.	5 years (duration of study)
scRNA-seq analyses of peripheral blood mononuclear cells	Investigators will examine the effect of probiotic supplementation on peripheral blood mononuclear cells using single cell RNA sequencing analysis.	5 years (duration of study)

Collaborators and Investigators

• Sponsor: Medical College of Wisconsin

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2021
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: March 27, 2020
• First Submitted That Met QC Criteria: April 2, 2020
• First Posted (Actual): April 6, 2020

Study Record Updates

• Last Update Posted (Actual): March 16, 2026
• Last Update Submitted That Met QC Criteria: March 12, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Probiotic; Newly diagnosed; New onset; Recent onset; Lactiplantibacillus plantarum; Lp299v
• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Autoimmune Diseases; Immune System Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 1
• Other Study ID Numbers: 1560525

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No